Montelukast as a Controller of Atopic Syndrome

Condition(s) targeted: Seasonal Allergic Rhinitis; Allergic Conjunctivitis; Atopic Eczema; Asthma

Intervention: montelukast (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Helsinki University

Official(s) and/or principal investigator(s):
Tari Haahtela, Professor, Principal Investigator, Affiliation: Skin and Allergy Hospital, Helsinki University Hospital

The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.

Official title: Montelukast as a Controller of Atopic Syndrome

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Crossover Assignment, Efficacy Study

Primary outcome: Allergic symptoms

Secondary outcome:

Need for antihistamines or inhaled beta-2-agonists to relieve symptoms

Exhaled nitric oxide concentration

Minimum age: 18 Years. Maximum age: 40 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Wheal diameter at least 4 mm in skin-prick test for both birch and timothy

- Allergic symptoms in both upper airways (allergic rhinitis) and lower airways

(asthma-like symptoms or diagnosed asthma) and at least one of the following:

- Allergic conjunctivitis

- Atopic eczema

- Oral symptoms from vegetables or fruits by cross reactivity to birch

- Urticaria in allergen exposure

Exclusion Criteria:

- Need for regular treatment with glucocorticoids

- Current smoking

- Other major disease or need for regular drug treatment

- Pregnancy

Skin and Allergy Hospital, Helsinki University Hospital, Helsinki 00029 HUS, Finland

Starting date: March 2007
Ending date: July 2007
Last updated: November 15, 2007